The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.
This webpage serves as notice under 35 U.S.C. §287(a) that the following products are protected by one or more U.S. patents. Each product also may be covered by one or more foreign patents, and additional patent application(s) may be pending.
The following list of products and U.S. patents may not be all inclusive, and other products not listed here may be protected by one or more patents.
|Alfapump® system||Covered by one or more of the following U.S patents: 7195608, 7621886, 7909790, 8517973, 9039652, 9149613, 9421347, 9913968, and 10252037, international equivalents, or one or more of the patents referenced at www.sequanamedical.com/patents. Other patents pending.|
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.